Hemab
Hemab is a clinical-stage biotech company developing prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders.
Operating in biotechnology, life science, pharmaceutical based in European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA), Hemab was founded in 2017.
The company sits in the biotechnology, life science, pharmaceutical segment, where it competes on its core product or service.
European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA) is where the company is located.
Its current recorded stage is Series_B.
Recorded headcount: c_00011_00050 employees.
It has disclosed roughly $190M in funding.
| Sector | Biotechnology, Life Science, Pharmaceutical |
|---|---|
| Headquarters | European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA) |
| Country | DK |
| Founded | 2017 |
| Employees | c_00011_00050 |
| Stage | series_b |
| Total funding | $190,000,000 |
Website: www.hemab.com
Browse related
Sign in to view the contact information we hold for Hemab.
Create a free account
Create a free account